The American Kidney Fund (AKF) announced today its 2026 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program. Corporate Members support AKF in fighting ...

Travere Therapeutics is awaiting an FDA decision on a label expansion for FILSPARI in focal segmental glomerulosclerosis, a ...

Learn more about whether Relay Therapeutics, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026. ・Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

According to TipRanks.com, Skor is a 4-star analyst with an average return of 15.8% and a 61.2% success rate. Skor covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, ...

Morgans healthcare analyst Iain Wilkie highlights seven ASX companies with upcoming catalysts in 2026. ... Read More The post ...

A year after revealing his “Liberation Day” trade policy initiatives, U.S. President Donald Trump is set to announce tariffs ...

Idiopathic Membranous Nephropathy Market Is Predicted To Reach USD 1 Billion By 2036 Due To Rising Therapeutic Options ...

Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant ...

Continued FDA approval of iptacopan was contingent on 2-year trial data ...